Clinical trial

A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination

NCT03858348

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2019-05-01

PhaseN/A

Study timeline

Study start (actual)2019-05-01Date precision: day

Registry last updated2024-02-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

COPDunresolved

COPD Exacerbationunresolved

Interventions

Sponsors & collaborators

Elpen Pharmaceutical Co. Inc.lead sponsor

Mapped research locations

ThessalonikiGreece1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03858348 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.